5-fluoropyrimidine has been researched along with oxonic acid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schöffski, P | 1 |
| Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G | 1 |
| Kobayashi, M; Kodera, Y; Macdonald, JS; Miyashita, Y; Morita, S; Sakamoto, J; Tsuburaya, A | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
2 review(s) available for 5-fluoropyrimidine and oxonic acid
| Article | Year |
|---|---|
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dosage Forms; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Oxonic Acid; Prodrugs; Pyridines; Pyrimidines; Tegafur | 2004 |
[5 -fluoropyrimidines for treatment of biliary tract cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Pyrimidines; Tegafur; Uracil | 2006 |
2 trial(s) available for 5-fluoropyrimidine and oxonic acid
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Time Factors | 2004 |
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Endpoint Determination; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Uracil | 2005 |